Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Sanofi-Aventis Sa (SNY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 105,311,008
  • Shares Outstanding, K 2,574,210
  • Annual Sales, $ 38,710 M
  • Annual Income, $ 4,898 M
  • 36-Month Beta 0.97
  • Price/Sales 2.58
  • Price/Book 1.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.80 +4.43%
on 11/23/16
42.42 -4.48%
on 11/10/16
+0.89 (+2.25%)
since 11/07/16
3-Month
36.81 +10.08%
on 10/26/16
42.42 -4.48%
on 11/10/16
+0.92 (+2.32%)
since 09/07/16
52-Week
36.81 +10.08%
on 10/26/16
44.50 -8.94%
on 04/21/16
-2.84 (-6.55%)
since 12/07/15

Most Recent Stories

More News
Novo Nordisk Files Regulatory Application for Semaglutide

Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal...

Alnylam Reports Positive Data on Fitusiran, Givosiran

Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays

The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays

Top Research Reports for 29th November, 2016

Top Research Reports for 29th November, 2016

Celgene vs. Regeneron: Which Stock is a Better Pick?

Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Shire

Pre-market, Stock-Callers.com follows the performances of four major players in the Drug Manufacturers space: Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Sanofi (NYSE: SNY), Biostar Pharmaceuticals Inc....

Glaxo Files for COPD Drug; FluLaval Approved for Infants

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) announced filing of a regulatory submission in the U.S. for a once-daily, closed triple combination therapy and received approval from the FDA for a...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 41.07
1st Resistance Point 40.80
Last Price 40.52
1st Support Level 40.13
2nd Support Level 39.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.